FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Ti Hamo and Hadrood of Hopotang Forcest					2. Issuer Name and Ticker or Trading Symbol OPKO HEALTH, INC. [OPK] 3. Date of Earliest Transaction (Month/Day/Year)												/ner	
(Last)	`	First)	(Middle)		02/10/2023							X	Officer (gi below)			Other (specify below)		
OPKO HEALTH, INC.													V1	ce Chair	man &	t CTO		
4400 BISCAYNE BLVD.					4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
(Street)														•	•	-	- Danaa	
MIAMI	I	FL	33137										Form illed	by More	than Or	ne Reporting	y Person	
(City)	(State)	(Zip)															
			Table I - No	n-Deri	vati	ve Secui	ities Acq	uired,	Disp	osed of,	or Bene	eficially Ow	ned					
1. Title of Security (Instr. 3)			2. Trans Date (Month		Year) Exec	2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Disp		ecurities Acquired (A) or osed Of (D) (Instr. 3, 4 a		nd 5) Securities Beneficially Following I			Direct (D) rect (I) 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
						Code	v	Amount	(A) o (D)	r Price		ransaction(s) nstr. 3 and 4)						
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative	se (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Deri Code (Instr. Acq 8) Disp		Acquired (rivative Securities quired (A) or sposed of (D) (Instr.		6. Date Exercisable and Expiration Date (Month/Day/Year)				8. Price of Derivative Security (Instr. 5)	9. Number derivative Securitie Beneficia Owned	es ally	10. Ownership Form: Direct (D) or Indirect	Beneficial Ownership (Instr. 4)	
	Security			Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amount or Number of Shares		Following Reported Transact (Instr. 4)	tion(s)	(I) (Instr. 4)	<u> </u>	
5% Convertible Promissory Notes due 2023	\$5	02/10/2023		D ⁽¹⁾			\$5,000,000	(1)		02/27/2023	Common Stock	\$5,000,000	\$5,000,000	\$0.00	00	D		
5% Convertible Promissory Notes due 2025	\$1.66	02/10/2023		A ⁽¹⁾		\$5,000,000		(1)		01/31/2025	Common Stock	\$5,000,000	\$5,000,000	\$5,000,	,000	D		

Explanation of Responses:

1. The two reported transactions involved an amendment and restatement of an outstanding convertible promissory note (the "Original Note"), resulting in the deemed cancellation of the Original Note and the execution of an amended note (the "Amended Note"). The Original Note was entered into on February 27, 2018 and the Reporting Person had the option to convert all or any portion of the outstanding principal balance of the Original Note, plus unpaid interest, into shares of the Issuer's common stock, par value \$0.01 per share, at a conversion price of \$5.00 per share, at any time prior to the maturity date, which was February 27, 2023. The Amended Note extends the maturity to January 31, 2025, and resets the conversion price to the 10 day volume weighted average price immediately preceding the date of the Amended Note, plus a 25% conversion premium, or \$1.66.

Remarks:

Steven D. Rubin, Attorney-in-Fact 02/14/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.